Lv5
1240 积分 2021-08-02 加入
Final results and predictive biomarkers of response and long-term outcomes with first-line pembrolizumab monotherapy in advanced renal cell carcinoma in the phase II KEYNOTE-427 study
13天前
已完结
Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer
22天前
已完结
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy
1个月前
已完结
Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial
1个月前
已完结
Evidence for metastasis-directed therapy in oligometastatic prostate cancer
1个月前
已完结
Renal cell carcinoma: molecular understanding and therapeutic development
1个月前
已完结
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study
1个月前
已完结
Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial
1个月前
已关闭
Dual-modal immunoassay for prostate cancer-derived exosomes enabled by a black phosphorus/silver SERS substrate and Yb/Er co-doped NaGdF4 UCL nanoprobes
1个月前
已关闭
Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients’ selection
2个月前
已完结
皖公网安备34019202002308
